- Raw materials
- Immunomodulators
- Monoclonal antibodies
- Trastuzumab
- Suppliers by country
- United States
Filters
Filter
Custom request?
Type
Production region
Qualifications
Country of origin
Trastuzumab API from United States Manufacturers & Suppliers
5 verified results
Take control of your API sourcing
Submit a Special Inquiry and have Pharmaoffer activate verified suppliers.
Commercial-scale Suppliers
Producer
Produced in
China|
Employees: 10+
|
Audit Report:
Certifications:
GMP
|
USDMF|
CoAAll certificates
GMP
USDMF
CoA
Distributor
Produced in
United States|
Employees: 200+
|
Audit Report:
Certifications:
GMP
|
USDMF|
CoA|
WHO-GMPAll certificates
GMP
USDMF
CoA
WHO-GMP
Take control of your API sourcing
Submit a Special Inquiry and have Pharmaoffer activate verified suppliers.
Producer
Produced in
Austria|
Audit Report:
Certifications:
GMP
|
CoAAll certificates
GMP
CoA
Producer
Produced in
South Korea|
Audit Report:
Certifications:
JDMF
|
CoAAll certificates
JDMF
CoA
Producer
Produced in
India|
Employees: 10000
|
Audit Report:
Certifications:
GMP
|
CoAAll certificates
GMP
CoA
Get full market intelligence report
€399,-
All Trastuzumab data. Full access. Full negotiation power
When insight is your advantage
Full data, full access, full negotiation power
Total market transparency
|
Supplier trade data access
|
Buyer / supplier flow comparison
Trusted by 30,000+ registered pharma professionals:
Reach multinationals, SMEs, compounding pharmacies & more!
Trastuzumab | CAS No: 180288-69-1 | GMP-certified suppliers
A medication that treats HER2‑positive breast and certain metastatic gastric cancers, supporting reliable oncology regimens for diverse clinical settings.
Therapeutic categories
Amino Acids, Peptides, and ProteinsAntibodiesAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsAntineoplastic Agents, Immunological
Generic name
Trastuzumab
Molecule type
biotech
CAS number
180288-69-1
DrugBank ID
DB00072
Approval status
Approved drug, Investigational drug
ATC code
L01FD01
Primary indications
- For the adjuvant treatment of HER2-overexpressing breast cancer, trastuzumab is indicated in several clinical settings: as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel
- As part of a treatment regimen with docetaxel and carboplatin
- Or as monotherapy following multi-modality anthracycline-based therapy
Product Snapshot
- Trastuzumab is an injectable monoclonal antibody available as IV or subcutaneous formulations, typically supplied as lyophilized powder or solution for reconstitution
- Its primary uses are for HER2‑positive breast cancer across early, adjuvant, and metastatic settings, as well as HER2‑overexpressing metastatic gastric and gastroesophageal junction adenocarcinoma
- The product is approved in major markets including the US, Canada, and the EU
Clinical Overview
Trastuzumab (CAS 180288-69-1) is a recombinant humanized IgG1 kappa monoclonal antibody produced in CHO cells. It binds with high affinity to the extracellular domain of HER2, a transmembrane receptor tyrosine kinase overexpressed in approximately 20 to 30 percent of breast cancers. Clinical use spans adjuvant, neoadjuvant, and metastatic HER2‑positive breast cancer, delivered as monotherapy or in combination with cytotoxic agents including anthracyclines, taxanes, carboplatin, and endocrine therapy in postmenopausal settings. It is also indicated with cytotoxic backbones for HER2‑overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. Subcutaneous presentations combine trastuzumab with hyaluronidase, and some regimens co-administer pertuzumab.
Pharmacodynamically, trastuzumab inhibits proliferation of HER2‑overexpressing tumor cells and mediates antibody‑dependent cellular cytotoxicity. It also reduces HER2 signaling through receptor downmodulation and blockade of extracellular domain cleavage.
The mechanism of action involves binding to the extracellular region of HER2, preventing receptor activation and limiting downstream pathways including MAPK and PI3K/Akt. This promotes cell cycle arrest and reduces tumor cell survival. Natural killer cell recruitment drives additional cytotoxic effects. Intrinsic or acquired resistance has been associated with PI3K pathway activation, PTEN deficiency, and compensatory growth factor receptor signaling.
Trastuzumab exhibits target-mediated disposition, long systemic half‑life typical of IgG1 antibodies, and is cleared primarily through catabolism. No clinically meaningful QTc effects have been observed.
Safety considerations include infusion reactions, cardiotoxicity risk particularly with anthracyclines, and rare severe hypersensitivity. Monitoring of left ventricular function is standard. Toxicities in gastric cancer regimens reflect combined cytotoxic exposures.
Notable brands and biosimilars include Herceptin, Ogivri, Herzuma, Kanjinti, Ontruzant, and Herwenda, with global approvals across major regulatory agencies.
For API sourcing, procurement should confirm CHO‑based biologic manufacturing controls, validated cell bank lineage, robust viral safety steps, and analytical comparability aligned with biosimilar and biologics quality guidelines.
Pharmacodynamically, trastuzumab inhibits proliferation of HER2‑overexpressing tumor cells and mediates antibody‑dependent cellular cytotoxicity. It also reduces HER2 signaling through receptor downmodulation and blockade of extracellular domain cleavage.
The mechanism of action involves binding to the extracellular region of HER2, preventing receptor activation and limiting downstream pathways including MAPK and PI3K/Akt. This promotes cell cycle arrest and reduces tumor cell survival. Natural killer cell recruitment drives additional cytotoxic effects. Intrinsic or acquired resistance has been associated with PI3K pathway activation, PTEN deficiency, and compensatory growth factor receptor signaling.
Trastuzumab exhibits target-mediated disposition, long systemic half‑life typical of IgG1 antibodies, and is cleared primarily through catabolism. No clinically meaningful QTc effects have been observed.
Safety considerations include infusion reactions, cardiotoxicity risk particularly with anthracyclines, and rare severe hypersensitivity. Monitoring of left ventricular function is standard. Toxicities in gastric cancer regimens reflect combined cytotoxic exposures.
Notable brands and biosimilars include Herceptin, Ogivri, Herzuma, Kanjinti, Ontruzant, and Herwenda, with global approvals across major regulatory agencies.
For API sourcing, procurement should confirm CHO‑based biologic manufacturing controls, validated cell bank lineage, robust viral safety steps, and analytical comparability aligned with biosimilar and biologics quality guidelines.
Identification & chemistry
| Generic name | Trastuzumab |
|---|---|
| Molecule type | Biotech |
| CAS | 180288-69-1 |
| UNII | P188ANX8CK |
| DrugBank ID | DB00072 |
Pharmacology
| Summary | Trastuzumab is a humanized monoclonal antibody that targets the extracellular domain of the HER2 receptor, a tyrosine kinase frequently overexpressed in certain tumors. By blocking HER2 signaling and promoting receptor downregulation, it reduces activity of downstream pathways that drive cell growth and survival. The antibody also engages immune effector mechanisms, including antibody‑dependent cell‑mediated cytotoxicity, to enhance elimination of HER2‑expressing tumor cells. |
|---|---|
| Mechanism of action | Trastuzumab is a recombinant humanized IgG1 monoclonal antibody against the HER-2 receptor, a member of the epidermal growth factor receptors which is a photo-oncogene. Over-expressed in breast tumour cells, HER-2 overamplifies the signal provided by other receptors of the HER family by forming heterodimers . The HER-2 receptor is a transmembrane tyrosine kinase receptor that consists of an extracellular ligand-binding domain, a transmembrane region, and an intracellular or cytoplasmic tyrosine kinase domain. It is activated by the formation of homodimers or heterodimers with other EGFR proteins, leading to dimerization and autophosphorylation and/or transphosphorylation of specific tyrosine residues in EGFR intracellular domains . Further downstream molecular signaling cascades are activated, such as the Ras/Raf/mitogen-activated protein kinase (MAPK), the phosphoinositide 3-kinase/Akt, and the phospholipase Cγ (PLCγ)/protein kinase C (PKC) pathways that promote cell growth and survival and cell cycle progression . Due to upregulation of HER-2 in tumour cells, hyperactivation of these signaling pathways and abnormal cell proliferation is observed. Trastuzumab binds to the extracellular ligand-binding domain and blocks the cleavage of the extracellular domain of HER-2 to induce its antibody-induced receptor downmodulation , and subsequently inhibits HER-2-mediated intracellular signaling cascades. Inhibition of MAPK and PI3K/Akt pathways lead to an increase in cell cycle arrest, and the suppression of cell growth and proliferation . Trastuzumab also mediates the activation of antibody-dependent cell-mediated cytotoxicity (ADCC) by attracting the immune cells, such as natural killer (NK) cells, to tumor sites that overexpress HER-2 . While the drug alone has a minimal potential to induce complement-dependent cytotoxicity (CDC),one study demonstrated increased therapeutic effectiveness and a synergistic effect on uterine serous carcinoma cells _in vitro_ when used in combination with [pertuzumab], which also has minor effects on CDC alone. This study showed that only the combination of both cell-bound antibodies would be sufficient to bind and activate the complement component 1q (C1q) required to initiate the complement cascade reaction. Intrinsic trastuzumab resistance has been noted for some patients with HER-2 positive breast cancer. Mechanisms involving trastuzumab resistance include deficiency of phosphatase and tensin homologue and activation of phosphoinositide 3-kinase, and the overexpression of other surface receptors, such as insulin-like growth factor . |
| Pharmacodynamics | Trastuzumab exerts an antitumour activity and is used in the treatment of HER2-positive breast cancer. HER2 protein overexpression is observed in 20%-30% of primary breast cancers thus HER2 presents as a useful therapeutic target for the treatment of breast cancers. Trastuzumab has been shown, in both _in vitro_ assays and in animals, to inhibit the proliferation of human tumour cells that overexpress HER2. It works as a mediator of antibody-dependent cellular cytotoxicity, where it binds as an antibody to cells over-expressing HER2, leading to preferential cell death. Trastuzumab was also shown to inhibit angiogenesis of tumor cells _in vivo_ . Higher doses and longer dosing intervals show no significant benefit over standard dose schedules . In patients with HER2 positive solid tumours, trastuzumab did not exert any clinically significant QTc interval duration. |
Targets
| Target | Organism | Actions |
|---|---|---|
| Receptor tyrosine-protein kinase erbB-2 | Humans | binder, antibody |
ADME / PK
| Absorption | Peak and trough plasma concentrations at steady state (between weeks 16 and 32) were approximately 123 and 79 mcg/mL, respectively. At the highest weekly dose studied (500 mg), mean peak serum concentration was 377 mcg/mL. |
|---|---|
| Half-life | The terminal half-life is approximately 28 days,but may decrease with lower doses - at the 10mg and 500mg doses, half-lives averaged approximately 1.7 and 12 days, respectively. |
| Metabolism | After it binds to HER2, trastuzumab is metabolized intracellularly into smaller peptides and amino acids. |
| Route of elimination | Following metabolism, the complex elimination of trastuzumab in humans is mediated by epithelial cells in a dose-dependent (nonlinear) fashion.The renal excretion of trastuzumab is very low. |
| Clearance | The predicted steady-state clearance of trastuzumab is 0.173 - 0.337 L/day, dependent primarily on the dosing regimen.The clearance rate for subcutaneously administered trastuzumab, formulated with hyaluronidase for improved subcutaneous absorption, is 0.11 L/day. |
Formulation & handling
- Trastuzumab is a monoclonal antibody requiring parenteral administration, supplied mainly as lyophilized powder or ready‑to‑use solutions for IV or SC delivery.
- Reconstitution and dilution demand gentle handling to avoid protein denaturation, with attention to buffering, avoidance of agitation, and protection from excessive heat or light.
- Cold‑chain storage is required for both powder and solution presentations, with limited stability after reconstitution or dilution.
Regulatory status
| Lifecycle | The API’s Canadian patent expired in 2012, indicating long-standing loss of exclusivity and a mature competitive environment. With availability across the US, Canada, and the EU, the product is well established and likely subject to broad generic presence. |
|---|
| Markets | US, Canada, EU |
|---|
Supply Chain
| Supply chain summary | Trastuzumab is supplied primarily by the originator group associated with Roche/Genentech, with additional packaging entities contributing to distribution. Branded products are established across the US, Canada, and EU. The listed Canadian patent expiry in 2012 indicates that biosimilar competition is already present or well‑established in these markets. |
|---|
Safety
| Toxicity | There is no experience with overdosage of trastuzumab in clinical trials - single doses >8 mg/kg have not been tested in humans.Trastuzumab can contribute to the development of ventricular dysfunction and congestive heart failure, particularly when used in combination (or temporally adjacent) to other cardiotoxic chemotherapies such as anthracyclines. |
|---|
High Level Warnings:
- High-dose exposure has not been characterized
- Human data above 8 mg/kg are lacking, so toxicological margins remain undefined
- Known risk for cardiotoxicity, including ventricular dysfunction and congestive heart failure, which is potentiated by concomitant or sequential anthracycline use
Trastuzumab is a type of Monoclonal antibodies
Monoclonal antibodies are a subcategory of pharmaceutical active pharmaceutical ingredients (APIs) that play a crucial role in the field of biopharmaceuticals. These antibodies are produced by cloning a single type of immune cell to create identical copies, allowing for targeted treatment of various diseases.
Monoclonal antibodies have gained significant attention in recent years due to their potential in treating a wide range of conditions, including cancer, autoimmune disorders, and infectious diseases. Their specificity and ability to bind to specific antigens make them highly effective therapeutic agents.
These pharmaceutical APIs are typically developed using hybridoma technology or recombinant DNA technology. Hybridoma technology involves fusing antibody-producing cells with immortalized cells to create hybrid cells that produce large quantities of monoclonal antibodies. Recombinant DNA technology, on the other hand, utilizes genetically engineered organisms such as bacteria or mammalian cells to produce monoclonal antibodies.
The production of monoclonal antibodies requires stringent quality control measures to ensure purity, potency, and safety. Extensive characterization and validation tests are conducted to assess their binding specificity, stability, and absence of contaminants.
Monoclonal antibodies have revolutionized the pharmaceutical industry, offering personalized treatment options and improving patient outcomes. They provide targeted therapy with fewer side effects compared to traditional treatments. The development and use of monoclonal antibodies continue to expand, with ongoing research aiming to enhance their effectiveness and broaden their applications.
In summary, monoclonal antibodies represent a significant advancement in the field of biopharmaceuticals, offering targeted therapy for a variety of diseases. Their precise mechanism of action and potential for personalized treatment make them a promising class of pharmaceutical APIs.
Trastuzumab (Monoclonal antibodies), classified under Immunomodulators
Immunomodulators, a category of pharmaceutical active pharmaceutical ingredients (APIs), are substances that help regulate and modify the immune response of an individual. These compounds play a crucial role in treating various immune-related disorders and diseases. Immunomodulators work by either enhancing or suppressing the immune system, depending on the specific condition being treated.
Immunomodulators are used in the treatment of autoimmune disorders, such as rheumatoid arthritis, multiple sclerosis, and psoriasis. By suppressing the immune system, these APIs help reduce the overactive immune response associated with these conditions, thereby alleviating symptoms and preventing further damage to the body's tissues.
On the other hand, immunomodulators are also employed to boost the immune system in cases of immunodeficiency disorders. These APIs stimulate the immune response, enabling the body to better fight off infections and diseases. Additionally, immunomodulators are utilized in the prevention and treatment of organ transplant rejection, where they help modulate the immune system to accept the transplanted organ.
The development and production of immunomodulators require rigorous testing and quality control to ensure their safety and efficacy. Pharmaceutical companies carefully formulate these APIs into various dosage forms, including tablets, capsules, injections, and topical preparations, to cater to different patient needs.
In summary, immunomodulators form a vital category of pharmaceutical APIs that regulate and modify the immune system. With their ability to modulate immune responses, these compounds contribute significantly to the management and treatment of various immune-related disorders and diseases, improving the quality of life for many patients.
Trastuzumab API manufacturers & distributors
Compare qualified Trastuzumab API suppliers worldwide. We currently have 5 companies offering Trastuzumab API, with manufacturing taking place in 5 different countries. Use the table below to review supplier type, countries of origin, certifications, product portfolio and GMP audit availability.
| Supplier | Type | Country | Product origin | Certifications | Portfolio |
|---|---|---|---|---|---|
| Apino Pharma Co., Ltd. | Producer | China | China | CoA, GMP, USDMF | 229 products |
| Biocon | Producer | India | India | CoA, GMP | 36 products |
| Celltrion | Producer | South Korea | South Korea | CoA, JDMF | 2 products |
| LGM Pharma | Distributor | United States | United States | CoA, GMP, USDMF, WHO-GMP | 441 products |
| Sandoz | Producer | Austria | Austria | CoA, GMP | 58 products |
When sending a request, specify which Trastuzumab API quality you need: for example EP (Ph. Eur.), USP, JP, BP, or another pharmacopoeial standard, as well as the required grade (base, salt, micronised, specific purity, etc.).
Use the list above to find high-quality Trastuzumab API suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our help page to learn more about sourcing APIs via Pharmaoffer.
Frequently asked questions about Trastuzumab API
Sourcing
What matters most when sourcing GMP-grade Trastuzumab?
Key considerations include verifying that the manufacturer complies with GMP standards recognized in the US, Canada, and the EU. Given that originator supply is concentrated with Roche/Genentech and biosimilars are established, confirming the regulatory status and inspection history of the specific producing and packaging sites is essential. It is also important to ensure traceable documentation for each stage of manufacturing and distribution.
Which documents are typically required when sourcing Trastuzumab API?
Request the core API documentation set: CoA (5 companies), GMP (4 companies), USDMF (2 companies), JDMF (1 company), WHO-GMP (1 company). Confirm versions and validity dates match the destination market to avoid delays in qualification.
Which manufacturers are known to produce Trastuzumab API?
Known or reported manufacturers for Trastuzumab: Apino Pharma Co., Ltd., LGM Pharma. Evaluate their GMP history, scale, and regional coverage before requesting dossiers or allocating demand.
How can I request quotes for Trastuzumab API from GMP suppliers?
Submit quote requests through the supplier listings with your specs and required documents (specifications, target volume, delivery timeline, and destination). Providing consistent details upfront speeds comparable offers and clarifies technical feasibility.
Is a GMP audit report available for Trastuzumab manufacturers?
Audit reports may be requested for Trastuzumab: 2 GMP audit reports available. Confirm the scope and recency of any audit before relying on it for qualification decisions.
How many suppliers offer Trastuzumab API on Pharmaoffer?
Reported supplier count for Trastuzumab: 5 verified suppliers. Filter listings by certifications, regions, and delivery options to match your qualification plan.
Which countries are known to manufacture Trastuzumab API?
Production countries reported for Trastuzumab: China (1 producer), United States (1 producer), India (1 producer). Knowing the manufacturing geography helps anticipate logistics lead times and import compliance needs.
Which certifications do suppliers of Trastuzumab usually hold?
Common certifications for Trastuzumab suppliers: CoA (5 companies), GMP (4 companies), USDMF (2 companies), JDMF (1 company), WHO-GMP (1 company). Always verify issuing authorities and expiry dates when reviewing audit packages.
Technical
What is Trastuzumab (CAS 180288-69-1) used for?
Trastuzumab is used to treat HER2‑positive breast cancer in adjuvant, neoadjuvant, and metastatic settings, either alone or with cytotoxic agents such as anthracyclines, taxanes, carboplatin, or endocrine therapy. It is also used with chemotherapy for HER2‑overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. Subcutaneous formulations combine Trastuzumab with hyaluronidase, and some regimens include co‑administration with pertuzumab.
Which therapeutic class does Trastuzumab fall into?
Trastuzumab belongs to the following therapeutic categories: Amino Acids, Peptides, and Proteins, Antibodies, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Agents. This positioning helps teams compare alternative APIs, anticipate pharmacology expectations, and align early research priorities.
What conditions is Trastuzumab mainly prescribed for?
The primary indications for Trastuzumab: For the adjuvant treatment of HER2-overexpressing breast cancer, Trastuzumab is indicated in several clinical settings: as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel, As part of a treatment regimen with docetaxel and carboplatin, Or as monotherapy following multi-modality anthracycline-based therapy. These use cases frame the target patient populations and help prioritize formulation and safety evaluations.
How does Trastuzumab work?
Trastuzumab is a recombinant humanized IgG1 monoclonal antibody against the HER-2 receptor, a member of the epidermal growth factor receptors which is a photo-oncogene. Over-expressed in breast tumour cells, HER-2 overamplifies the signal provided by other receptors of the HER family by forming heterodimers . The HER-2 receptor is a transmembrane tyrosine kinase receptor that consists of an extracellular ligand-binding domain, a transmembrane region, and an intracellular or cytoplasmic tyrosine kinase domain. It is activated by the formation of homodimers or heterodimers with other EGFR proteins, leading to dimerization and autophosphorylation and/or transphosphorylation of specific tyrosine residues in EGFR intracellular domains . Further downstream molecular signaling cascades are activated, such as the Ras/Raf/mitogen-activated protein kinase (MAPK), the phosphoinositide 3-kinase/Akt, and the phospholipase Cγ (PLCγ)/protein kinase C (PKC) pathways that promote cell growth and survival and cell cycle progression . Due to upregulation of HER-2 in tumour cells, hyperactivation of these signaling pathways and abnormal cell proliferation is observed. Trastuzumab binds to the extracellular ligand-binding domain and blocks the cleavage of the extracellular domain of HER-2 to induce its antibody-induced receptor downmodulation , and subsequently inhibits HER-2-mediated intracellular signaling cascades. Inhibition of MAPK and PI3K/Akt pathways lead to an increase in cell cycle arrest, and the suppression of cell growth and proliferation . Trastuzumab also mediates the activation of antibody-dependent cell-mediated cytotoxicity (ADCC) by attracting the immune cells, such as natural killer (NK) cells, to tumor sites that overexpress HER-2 . While the drug alone has a minimal potential to induce complement-dependent cytotoxicity (CDC),one study demonstrated increased therapeutic effectiveness and a synergistic effect on uterine serous carcinoma cells _in vitro_ when used in combination with [pertuzumab], which also has minor effects on CDC alone. This study showed that only the combination of both cell-bound antibodies would be sufficient to bind and activate the complement component 1q (C1q) required to initiate the complement cascade reaction.
Intrinsic Trastuzumab resistance has been noted for some patients with HER-2 positive breast cancer. Mechanisms involving Trastuzumab resistance include deficiency of phosphatase and tensin homologue and activation of phosphoinositide 3-kinase, and the overexpression of other surface receptors, such as insulin-like growth factor .
What should someone know about the safety or toxicity profile of Trastuzumab?
Trastuzumab’s principal safety concern is cardiotoxicity, including ventricular dysfunction and congestive heart failure, with higher risk when used with anthracyclines. Infusion‑related reactions and rare severe hypersensitivity can occur. Human data at high doses beyond 8 mg/kg are limited, so the toxicological margin is not well defined. Routine monitoring of left‑ventricular function is standard, and additional toxicities in combination regimens reflect the companion cytotoxic agents.
What are important formulation and handling considerations for Trastuzumab as an API?
Trastuzumab is formulated as a monoclonal antibody for parenteral use, typically supplied as a lyophilized powder or ready‑to‑use solution for IV or SC administration. Reconstitution and dilution require gentle mixing, appropriate buffering, and protection from heat and light to prevent protein denaturation. Both powder and solution require cold‑chain storage, and stability after reconstitution or dilution is limited. Avoiding excessive agitation during handling is essential to maintain protein integrity.
Is Trastuzumab a biotech?
Trastuzumab is classified as a biotech. That classification shapes process design, impurity profiling, and analytical control strategies.
Are there special stability concerns for oral Trastuzumab?
Trastuzumab is formulated only for parenteral use, and the provided context describes stability requirements for lyophilized powder and ready‑to‑use solutions. Because it is a monoclonal antibody requiring cold‑chain storage and careful handling to prevent denaturation, it is not suitable for oral administration. Therefore, no oral‑specific stability considerations apply.
Regulatory
Where is Trastuzumab approved or in use globally?
Trastuzumab is reported as approved in the following major regions: US, Canada, EU. Understanding geographic coverage informs regulatory filings, supply planning, and risk assessments before escalating procurement.
What’s the regulatory and patent landscape for Trastuzumab right now?
Trastuzumab is subject to established regulatory pathways in the US, Canada, and the EU, where it is approved and governed under each region’s biologics oversight framework. Its patent landscape is defined by jurisdiction‑specific protections for the reference product and subsequent biosimilar entries, with timelines and scope determined by local intellectual property laws.
Pharmaoffer
How does Pharmaoffer’s Smart Sourcing Service help with Trastuzumab procurement?
Pharmaoffer's Smart Sourcing Service coordinates compliant suppliers, documentation, and competitive quotes for Trastuzumab. It centralizes outreach, follow-ups, and document validation to shorten procurement timelines.
Is Trastuzumab included in the PRO Data Insights coverage?
PRO Data Insights coverage for Trastuzumab: 32 verified transactions across 15 suppliers and 11 buyers worldwide. Use the dataset to benchmark suppliers and monitor regulatory activity where available.
Where can I access the API market report for Trastuzumab?
Market report availability for Trastuzumab: Report Available. The report highlights demand trends, pricing drivers, and supplier landscape insights for procurement planning.
